Overview
Ketamine exists as two mirror-image molecules: S-ketamine (esketamine) and R-ketamine (arketamine). Racemic ketamine contains equal parts of both enantiomers and has been used in anesthesia since 1970. Esketamine, the purified S-enantiomer, received FDA approval as Spravato (intranasal spray) in March 2019 specifically for treatment-resistant depression.
Pharmacology
| Property | Esketamine | Racemic Ketamine |
|---|---|---|
| Composition | Pure S-enantiomer | 50/50 S- and R-enantiomers |
| NMDA receptor affinity | 3 to 4 times greater than R-ketamine | Mixed (S stronger, R weaker) |
| Route | Intranasal (Spravato) | IV, IM, sublingual, oral, intranasal |
| Bioavailability | ~48 percent (intranasal) | ~100 percent (IV), 17-30 percent (oral/sublingual) |
Esketamine has approximately 3 to 4 times greater binding affinity for the NMDA receptor compared to arketamine. However, potency at a single receptor does not necessarily predict superior antidepressant efficacy. Preclinical research suggests arketamine may contribute unique antidepressant properties through sigma-1 receptor modulation and potentially more sustained BDNF pathway engagement.
Clinical Evidence
Esketamine has FDA approval based on five Phase III trials (TRANSFORM-1, -2, -3, SUSTAIN-1, -2) conducted by Janssen Pharmaceuticals. TRANSFORM-2 demonstrated statistically significant improvement in MADRS scores versus placebo at 28 days.
Racemic IV ketamine has over 40 published RCTs, but no pharmaceutical company has pursued FDA approval for the generic compound. Head-to-head trials comparing racemic IV ketamine to intranasal esketamine are limited. A Correia-Melo et al. (2020) non-inferiority trial suggested comparable efficacy, though the study had methodological limitations.
Cost and Insurance
| Factor | Esketamine (Spravato) | Racemic Ketamine |
|---|---|---|
| Drug cost per session | $590 to $885 | $5 to $15 (generic) |
| Total session cost | $800 to $1,200 | $400 to $800 (IV) |
| Insurance coverage | Often covered with prior auth | Rarely covered |
| REMS requirement | Yes (certified centers only) | No |
| Out-of-pocket | Varies with copay/deductible | Full cost typically |
The cost calculus is complex. Esketamine's list price is high, but insured patients may pay only their copay or deductible. Racemic ketamine is inexpensive as a drug but is paid out-of-pocket because its use for depression is off-label.
Administration and Monitoring
Both treatments require administration in a certified healthcare setting with monitoring. Spravato sessions require a 2-hour observation period with blood pressure monitoring at 40 minutes and 2 hours post-dose. IV racemic ketamine monitoring varies by clinic but typically includes continuous pulse oximetry and blood pressure monitoring during and for 30 to 60 minutes after infusion.
Side Effect Comparison
Both esketamine and racemic ketamine produce similar acute side effects: dissociation, dizziness, nausea, and transient blood pressure elevation. Some clinicians report that racemic ketamine produces a somewhat different dissociative quality compared to pure esketamine, potentially due to arketamine's contribution, though this observation has not been rigorously studied.
References
- Popova et al. — TRANSFORM-2 Trial — Esketamine for treatment-resistant depression
- Correia-Melo et al. — Racemic vs Esketamine — Comparative study of racemic ketamine and esketamine
- Yang et al. — Arketamine Research — R-ketamine: a rapid-onset and sustained antidepressant
- FDA — Spravato Prescribing Information — Spravato label
Verdict
Esketamine offers the advantage of FDA approval and potential insurance coverage through a standardized nasal spray delivery system. Racemic ketamine provides lower per-treatment costs, flexible dosing across multiple routes, and may benefit from the unique properties of arketamine. Neither is definitively superior in efficacy. The choice often depends on insurance coverage, provider availability, and individual response.
Share